Natco Pharma [NATCOPHARM] vs Laurus Labs [LAURUSLABS] Detailed Stock Comparison

Natco Pharma Ltd.

NSE
Loading...

Laurus Labs Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Natco Pharma Ltd. wins in 15 metrics, Laurus Labs Ltd. wins in 5 metrics, with 0 ties. Natco Pharma Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Natco Pharma Ltd. Laurus Labs Ltd. Better
P/E Ratio (TTM) 12.32 70.26 Natco Pharma Ltd.
Price-to-Book Ratio 2.22 12.32 Natco Pharma Ltd.
Debt-to-Equity Ratio 3.01 44.83 Natco Pharma Ltd.
PEG Ratio 0.89 0.06 Laurus Labs Ltd.
EV/EBITDA 9.10 37.60 Natco Pharma Ltd.
Profit Margin (TTM) 34.13% 12.55% Natco Pharma Ltd.
Operating Margin (TTM) 17.38% 20.22% Laurus Labs Ltd.
EBITDA Margin (TTM) 17.38% 20.22% Laurus Labs Ltd.
Return on Equity 24.77% 7.79% Natco Pharma Ltd.
Return on Assets (TTM) 21.85% 3.84% Natco Pharma Ltd.
Free Cash Flow (TTM) $11.85B $-393.50M Natco Pharma Ltd.
Dividend Yield 0.73% 0.21% Natco Pharma Ltd.
1-Year Return 4.09% 125.34% Laurus Labs Ltd.
Price-to-Sales Ratio (TTM) 4.21 8.81 Natco Pharma Ltd.
Enterprise Value $162.40B $623.27B Laurus Labs Ltd.
EV/Revenue Ratio 3.56 9.27 Natco Pharma Ltd.
Gross Profit Margin (TTM) 79.44% 60.94% Natco Pharma Ltd.
Revenue per Share (TTM) $255 $125 Natco Pharma Ltd.
Earnings per Share (Diluted) $86.97 $15.60 Natco Pharma Ltd.
Beta (Stock Volatility) 0.19 0.34 Natco Pharma Ltd.

Natco Pharma Ltd. vs Laurus Labs Ltd. Stock Performance Analysis

Loading Price Chart...

NATCOPHARM
LAURUSLABS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Natco Pharma Ltd.2.58%-3.30%-26.91%-14.99%-4.61%-2.74%
Laurus Labs Ltd.0.25%-3.63%9.96%33.20%37.74%25.57%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Natco Pharma Ltd.4.09%43.22%-18.62%70.53%1,506.26%4,700.64%
Laurus Labs Ltd.125.34%324.90%136.60%1,420.87%1,420.87%1,420.87%

Performance & Financial Health Analysis: Natco Pharma Ltd. vs Laurus Labs Ltd.

MetricNATCOPHARMLAURUSLABS
Market Information
Market Cap i₹191.91B₹609.64B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i701,4641,449,989
90 Day Avg. Volume i888,1691,817,191
Last Close₹863.90₹1,394.30
52 Week Range₹789.00 - ₹1,226.80₹641.05 - ₹1,457.00
% from 52W High-29.58%-4.30%
All-Time High₹1,639.00 (Sep 09, 2024)₹1,457.00 (Jun 08, 2026)
% from All-Time High-47.29%-4.30%
Growth Metrics
Quarterly Revenue Growth0.36%0.26%
Quarterly Earnings Growth0.14%1.73%
Financial Health
Profit Margin (TTM) i0.34%0.13%
Operating Margin (TTM) i0.17%0.20%
Return on Equity (TTM) i0.25%0.08%
Debt to Equity (MRQ) i3.0144.83
Cash & Liquidity
Book Value per Share (MRQ)₹482.88₹88.98
Cash per Share (MRQ)₹178.93₹1.18
Operating Cash Flow (TTM) i₹19.26B₹4.13B
Levered Free Cash Flow (TTM) i₹18.85B₹3.58B
Dividends
Last 12-Month Dividend Yield i0.73%0.21%
Last 12-Month Dividend i₹6.50₹2.00

Valuation & Enterprise Metrics Analysis: Natco Pharma Ltd. vs Laurus Labs Ltd.

MetricNATCOPHARM (Apr 24, 2026)LAURUSLABS (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i12.3270.26
Forward P/E i27.2658.80
PEG Ratio i0.890.06
Price to Sales (TTM) i4.218.81
Price to Book (MRQ) i2.2212.32
Market Capitalization
Market Capitalization i₹191.91B₹609.64B
Enterprise Value i₹162.40B₹623.27B
Enterprise Value Metrics
Enterprise to Revenue i3.569.27
Enterprise to EBITDA i9.1037.60
Risk & Other Metrics
Beta i0.190.34
Book Value per Share (MRQ) i₹482.88₹88.98

Financial Statements Comparison: Natco Pharma Ltd. vs Laurus Labs Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNATCOPHARM (2025)LAURUSLABS (2025)
Revenue/Sales i44.12B55.08B
Cost of Goods Sold i8.65B25.39B
COGS % of Revenue i19.6%46.1%
Gross Profit i35.46B29.68B
Gross Margin i80.4%53.9%
Research & Development i1.13B553.00M
Operating Income (EBIT) i19.81B6.25B
Operating Margin i44.9%11.4%
EBITDA i24.58B10.64B
EBITDA Margin i55.7%19.3%
Pre-Tax Income i22.91B4.84B
Pre-Tax Income % of Revenue i51.9%8.8%
Income Tax i4.08B1.30B
Income Tax % of Revenue i9.2%2.4%
Net Income (Profit) i18.83B3.58B
Profit Margin i42.7%6.5%

Balance Sheet & Liquidity Metrics

MetricNATCOPHARM (2025)LAURUSLABS (2025)
Cash & Equivalents i1.20B995.40M
Total Current Assets i52.70B43.32B
Total Current Assets % of Revenue i119.5%78.7%
Total Current Liabilities i9.44B35.40B
Total Current Liabilities % of Revenue i21.4%64.3%
Long-Term Debt i46.00M7.08B
Long-Term Debt % of Revenue i0.1%12.9%
Total Shareholders Equity i76.12B46.03B
Retained Earnings i62.47B36.26B
Retained Earnings % of Revenue i141.6%65.8%
Property, Plant & Equipment i474.00M1.89B

Cash Flow Statement Comparison

MetricNATCOPHARM (2025)LAURUSLABS (2025)
Operating Cash Flow i19.26B4.13B
Operating Cash Flow % of Revenue i43.7%7.5%
Capital Expenditures i-3.06B-5.41B
Free Cash Flow i11.85B-393.50M
FCF Margin i26.9%-0.7%
Debt Repayment iN/A-3.16B
Common Stock Repurchase i0N/A

Short Interest & Institutional Ownership Analysis

MetricNATCOPHARMLAURUSLABS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i179.11M539.86M
Float Shares i83.44M362.63M
% Held by Insiders i50.55%32.06%
% Held by Institutions i11.35%34.74%
% Held by Public i38.10%33.20%

Dividend Analysis & Yield Comparison: Natco Pharma Ltd. vs Laurus Labs Ltd.

MetricNATCOPHARMLAURUSLABS
Last 12-Month Dividend i₹6.50₹2.00
Last 12-Month Dividend Yield i0.73%0.21%
3-Year Avg Annual Dividend i₹7.25₹1.60
3-Year Avg Dividend Yield i0.24%0.15%
3-Year Total Dividends i₹21.75₹4.80
Ex-Dividend DateFeb 18, 2026Oct 31, 2025